Amgen announced on December 5, 2024, a $1 billion investment to build a second drug substance manufacturing facility in Holly Springs, North Carolina. The expansion will create 370 new jobs in the region. Combined with a previously announced $550 million commitment, Amgen’s total planned investment in Holly Springs now exceeds $1.5 billion.
What it means
The new facility adds a second drug substance manufacturing site for Amgen at its Holly Springs footprint. The company said the expansion is aimed at bringing medicines to patients. North Carolina Governor Roy Cooper said the investment raises the state’s standing as a center for biotechnology.
Key facts
- New investment: $1 billion for a second drug substance manufacturing facility (according to the company)
- Location: Holly Springs, North Carolina
- Jobs created: 370 new positions in the region (according to the company)
- Total planned investment in Holly Springs: more than $1.5 billion (according to the company)
- Prior commitment: $550 million, previously announced
- Announcement date: December 5, 2024
Source: Amgen news release (PRNewswire)